| 영문 | test | 한글 | 검사 |
|---|---|---|---|
| 설명 | 어떤 다른 물질을 검출, 측정, 생성하기 위한 특정한 화학반응을 일으키는데 사용되는 방법. |
||
| 영문 | scratch test | 한글 | 난절법 |
|---|---|---|---|
| 설명 | 피부를 날카로운 바늘로 긁어 피부의 반응을 보는 검사로 피부 과민반응이나 알레르기를 알아보기 위한 검사이다. 바늘끝에 항원을 묻힌 뒤, 피부밑을 긁어 반응을 알아본다. 이때 항원이 아닌 대조물질(예를 들어 보통의 물)을 묻힌 바늘을 같이 반응하여 피부묘기증(dermographism) 단지 바늘의 긁힘만으로 알레르기 같은 반응을 일으키는 현상과 감별해야 한다. 난청, 청력소실(hearing loss) 청각이 저하 또는 상실된 상태. 원인과 정도는 여러 가지인데, 난청은 그 정도가 가장 심한 상태이다. 청각의 전도경로에 장애가 있을 때 난청이 일어나고, 그 병터가 외이도나 중이에 있는 것을 전음난청, 내이에 있는 것을 감음 난청이라 하여 구분한다. 또 병터의 자리를 명시하여 중이성 난청이나 미로성 난청 등으로 세분하기도 한다. |
||
| 영문 | stool guaiac test | 한글 | 대변 구아이악 검사 |
|---|---|---|---|
| 설명 | 대변내에 있을 수 있는 잠혈(눈에 보이지 않는 출혈)유무를 검사하는 방법으로, 혈구내의 heme peroxidase에 의해 guaiac이 산화되는 반응을 이용하여 측정한다. 방법은 3일간에 걸쳐 한 변에서 2군데씩 채취하여 검사한다. 위양성 반응(거짓으로 혈액이 있다고 나타나는 반응)은 식물 과산화효소를 함유하고 있는 홍당무의 섭취나 혈구 성분을 함유하고 있는 고기 섭취 등에서 나타날 수 있으며, 위음성 반응(실제로 혈액은 있지만, 혈액이 없다고 나타나는 반응)은 환원력을 가지고 있는 비타민 C의 복용시 나타날 수 있다. 특히 위양성 반응이 매우 흔하다. |
||
| 영문 | Rorschach Test | 한글 | 로르샤하 검사 |
|---|---|---|---|
| 설명 | 사고장애와 정서장애에 민감한 투사검사(projective test). 검은색과 몇가지 색으로 이루어진 잉크얼룩같은 도형이 그려진 10개의 카드를 이용한다. 피검자에게 카드를 보이고 본 것에 대해 말하도록 한다. 다음에는 얼룩의 어느 위치가 피검자가 말한 지각대상을 암시하는지 찾도록 한다. 피검자의 답변을 분석하면 그의 사고와 정서상태에 대한 정보를 얻을 수 있다. |
||
| 영문 | Mantoux test | 한글 | 망토우검사 |
|---|---|---|---|
| 설명 | 소아에 주로 실시하는 검사 방법으로, BCG접종후에나 혹은 결핵균에 한번이라도 노출된 경우에 양성반응으로 나온다. 우리나라에서는 생후 1개월에 BCG예방접종을 시행하므로 대부분 양성으로 나오게 되나, 이 예방접종을 받지 않은 상태에서 양성으로 나오면, 결핵균의 침투를 의심할 수 있다. |
||
| HLA | histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod... |
|---|---|
| PAT | Pain Apperception Test; paroxysmal atrial tachycardia; patient; phenylaminotetrazole; physical abili... |
| BlT | bleeding time; blood test; blood type, blood typing |
| PLT | pancreatic lymphocytic infiltration; platelet; primed lymphocyte test; primed lymphocyte typing; psi... |
| CAT | California Achievement Test; capillary agglutination test; catalase; cataract; catecholamine; Childr... |
| HTC | Homozygous Typing Cell |
|---|---|
| MLST | Multi Locus Sequence Typing |
| PLT | Primed Lymphocyte Typing |
| SBT | Sequence-based typing |
| SBT | Sequencing Based Typing |
| bacterial typing techniques | Procedures for identifying types and strains of bacteria. The most frequently employed typing systems are bacteriophage typing and serotyping as well as bacteriocin typing and biotyping. (12 Dec 1998) |
|---|---|
| bacteriophage typing | A technique of bacterial typing which differentiates between bacteria or strains of bacteria by their susceptibility to one or more bacteriophages. (12 Dec 1998) |
| phage typing | <microbiology> Bacteria may be typed by their susceptibility to a range of bacteriophages though confusion may arise if the bacteria carry plasmids encoding restriction endonucleases. (18 Nov 1997) |
| mycological typing techniques | Procedures for identifying types and strains of fungi. (12 Dec 1998) |
| HLA typing | <immunology> Tests done in order to determine if a patient has antibodies against a potential donor's HLA antigens. The presence of antibodies means that a particular graft will be rapidly rejected. (05 Mar 2000) |
| DNA typing | <molecular biology> See restriction fragment length polymorphism. (18 Nov 1997) |
| tissue typing | <procedure> The process of determining the allelic types of the antigens of the major histocompatibility complex (MHC) that determine whether a tissue graft will be accepted or rejected. at present carried out either by use of polyclonal or monoclonal antibodies against MHC antigens or less usually by tests of MHC restricted cell function or skin grafting (the latter not in humans). (18 Nov 1997) |
| typing | Classification according to type. Origin: see type Bacteriophage typing, a microbiological procedure, of epidemiological importance, for distinguishing types within a seemingly homogeneous bacterial species or strain by the use of type-specific bacteriophage. HLA typing, tests done in order to determine if a patient has antibodies against a potential donor's HLA antigens. The presence of antibodies means that a particular graft will be rapidly rejected. Also used to establish paternity and in forensic medicine. (05 Mar 2000) |
| major histocompatibility antigen | <immunology> A set of plasmalemmal glycoprotein antigens involved in rapid (e.g. 7 days in the mouse) graft rejection and other immune phenomena. The minor histocompatibility antigens are involved in much slower rejection phenomena. The major antigens show remarkable polymorphism and occur as Class I and Class II types in mammals, birds may have a Class III molecule as well. See: histocompatibility antigens, MHC restriction. (18 Nov 1997) |
| major histocompatibility complex | The set of gene loci specifying major histocompatibility antigens, for example HLA in man, H 2 in mice, RLA in rabbits, RT 1 in rats, DLA in dogs, SLA in pigs, etc. Acronym: MHC (18 Nov 1997) |
| minor histocompatibility antigens | Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In the mouse they are coded by more than 500 genes at up to 30 minor histocompatibility loci. The most well-known minor histocompatibility antigen in mammals is the h-y antigen. (12 Dec 1998) |
| minor histocompatibility loci | Genetic loci responsible for the encoding of histocompatibility antigens other than those encoded by the major histocompatibility complex. The antigens encoded by these genes are often responsible for graft rejection in cases where histocompatibility has been established by standard tests. The location of some of these loci on the x and y chromosomes explains why grafts from males to females may be rejected while grafts from females to males are accepted. In the mouse roughly 30 minor histocompatibility loci have been recognised, comprising more than 500 genes. (12 Dec 1998) |
| H2 histocompatibility | <immunology> The ability of a tissue to be grafted from a donor to a host, without the host's immune system attacking the grafted tissue. The chances of H2 histocompatibility is determined by how well the tissue proteins (cell surface glycoproteins in the tissue, to be specific) match between donor and host. (09 Oct 1997) |
| histocompatibility | If tissues of two organisms are histocompatible, then grafts between the organisms will not be rejected. If, however, major histocompatibility antigens are different then an immune response will be mounted against the foreign tissue. (18 Nov 1997) |
| histocompatibility antigen | <immunology> A set of plasmalemmal glycoproteins on the surface of all nucleated cells that are crucial for T-cell recognition of antigens. Particularly the HLA system in humans and the H2 system in mice. They are the major antigens responsible for tissue recognition. For this reason, they are of prime importance in determining compatible organ donors for a specific transplantation procedure. Each person has unique HLA antigens. Some HLA antigens have been identified to be correlated with the presence of certain autoimmune diseases. One of these is the HLA-B27 site. Approximately 85% of patients with ankylosing spondylitis and Reiter's syndrome will have the HLA-B27 antigen present on the leukocytes. There are two classes of histocompatibility antigens: 1. Class I, histocompatibility antigens composed of two glycosylated subunits, a heavy chain of 44 kD and beta2 microglobulin (12 kD). The heavy chain may be coded by K, D or L genes of mouse H2 and A, B or C genes of human HLA complex. Class I antigens are important in T-cell killing and are recognised in conjunction with the foreign cell surface antigens MHC restriction). 2. Class II antigens, heterodimeric histocompatibility antigens composed of alpha (32 kD) and beta (28 kD) chains. Found mostly on B lymphocytes, macrophages and accessory cells. The response of T helper cells requires that the foreign antigen is presented in conjunction with the appropriate Class II antigens. (Murine H2 Ia antigens and human HLA DR antigens are Class II). (14 Oct 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|